EUVIMED · CrossrefZeitschrift
JTO Clinical and Research Reports
ISSN 2666-3643 · Elsevier BV
Neueste Artikel
Factors Affecting Ablation Zone Size Reaching Predicted During Bronchoscopic Microwave Ablation: A Retrospective Analysis
Disparities in Lung Cancer Screening: The Impact of Smoking Behavior on Eligibility
Multidisciplinary Management of Stage III NSCLC in the Immunotherapy Era: An Italian Delphi Consensus from AIOM, SICT, SIAPEC, and AIRO
Fluctuating Methylation-based ctDNA Detection in NSCLC Surveillance: Implications for Serial Monitoring and Specificity
Lung Cancer Screening Recommendations in the Elderly: International Society for Geriatric Oncology Consensus Statement
High PD-L1 Expression and Clinical Outcomes of First-Line Osimertinib in EGFR-Mutant NSCLC: A Multicenter Real-World Validation Study (WJOG 20724L)
Rethinking the Platinum Standard in SCLC: A Meta-Analysis of Limited- and Extensive-Stage Disease in the Immunotherapy Era
Dual Checkpoint Inhibition With or Without Chemotherapy in Metastatic NSCLC: A Reconstructed Individual Patient Data Meta-Analysis
Real-World Evidence of First- or Second-Line Immune Checkpoint Inhibitors Versus Chemotherapy in Advanced NSCLC: A Prospective Pragmatic Multicenter Korean Study
Brief Report: Reassessment of bTMB as a Predictive Biomarker in NSCLC Immunotherapy—A Reanalysis of OAK and POPLAR
Effect of Risedronate on Rib Cortical Thickness After Stereotactic Body Radiotherapy to Peripheral Lung Tumors: Results of a Randomized Phase 2 Trial
Toward Global Integration of Exercise in Lung Cancer Care: The IREX-Lung Initiative
Brief Report: Combination Capmatinib and Trametinib in Metastatic MET-Driven NSCLC
Outcomes of Platinum plus Pemetrexed Rechallenge in Pleural Mesothelioma: The Role of Platinum-Free Interval in a Multicenter Real-World Analysis
Optimizing Treatment Pathways With Multidisciplinary Team Discussions in Stage II to III NSCLC
Lung-Reporting and Data System Category (Lung-RADS) and Adherence to Low-Dose Computed Tomography Screening and Recommended Follow-Up: A Multicenter Cohort Study
Phlegmasia Cerulea Dolens and Pulmonary Embolism in a Patient With NSCLC Receiving Dual EGFR/MET Targeted Therapy: A Case Report
Perioperative Pembrolizumab in Japanese Participants With Early-Stage NSCLC: Subgroup Analysis From KEYNOTE-671
Dacomitinib With or Without Dose Titration in Treatment-Naive Advanced EGFR-Mutated NSCLC — Primary Analysis of the ATORG-003 Phase 2 Trial
Garsorasib (D-1553) in Combination With Pembrolizumab and Chemotherapy for First-Line Metastatic NSCLC With KRAS G12C Mutation: Results of a Phase 1b Study
Living With ALK Fusion-Positive NSCLC: A French Nationwide Survey of the Psychosocial Impact Among Patients, Caregivers, and Health Care Professionals
Prevalence of High Programmed Death-Ligand 1 Expression in Pulmonary Sarcomatoid Carcinoma: A Systematic Review and Meta-Analysis
SKYSCRAPER-05: A Phase 2 Study of Perioperative Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Patients With Previously Untreated, Locally Advanced, Resectable, Stage II‒IIIB NSCLC
BAP1 Loss in Pleural Mesothelioma Is Associated With Reduced Soluble CCL2 in Patient Effusion, Abrogated CCL2-Mediated Monocyte Recruitment In Vitro
Multi-Institutional Integration of Circulating miRNAs and Protein Tumor Markers for Early Lung Cancer Detection
Tarlatamab in Relapsed SCLC With Idiopathic Pulmonary Fibrosis: A Case With Comparative DLL3 Expression Analysis: Case Report
Triple-Targeted Therapy With Encorafenib, Binimetinib, and Osimertinib in EGFR-Mutated NSCLC With Acquired BRAF Alteration After Osimertinib: A Single-Center Experience
Rare ALK Fusions in NSCLC—Expanding the Boundaries of Precision Oncology
Clinicogenomic profiling of MET-driven non-small cell lung cancer in a nationwide Taiwanese cohort from the TCOG T1521 registry
CNS Efficacy of Osimertinib Plus Savolitinib in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With MET Overexpression and/or Amplification: A Brief Report
EUVIMED